Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: A systematic review and meta-analysis of the literature
- PMID: 18406100
- DOI: 10.1016/j.ejso.2008.01.034
Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: A systematic review and meta-analysis of the literature
Abstract
Background: Sentinel node biopsy became the standard of care before consensus on the technique was reached and without randomized studies having shown a similar or decreased axillary recurrence rate. The purpose of this study was to evaluate studies reporting on patients with a negative sentinel node biopsy.
Methods: We performed a systematic review and meta-analysis of the literature for studies concerning clinically node-negative breast cancer patients with a tumour-negative sentinel node biopsy and no subsequent axillary node dissection. The axillary recurrence rate was determined, as well as the sensitivity of the sentinel node procedure and the differences in lymphatic mapping techniques.
Results: Forty-eight studies concerning 14 959 sentinel node-negative breast cancer patients followed for a median of 34 months were selected. Sixty-seven patients developed an axillary recurrence, resulting in a recurrence rate of 0.3%. The sensitivity of the sentinel node biopsy was 100%. Uni- and multivariable variable analyses showed that the lowest recurrence rates were reported in studies performed in cancer centres, in studies that described the use of (99m)Tc-sulphur colloid, and also when investigators used the superficial injection technique or evaluated the harvested sentinel nodes with haematoxylin-eosin and immunohistochemistry staining (p<0.01).
Conclusions: In this systematic literature review, the axillary recurrence rate in sentinel node-negative patients is 0.3%, which is well within the desired range. The median sensitivity of the procedure appears to be as high as 100%. The recurrence rate is influenced by the differences in the lymphatic mapping technique.
Similar articles
-
Axillary treatment for operable primary breast cancer.Cochrane Database Syst Rev. 2017 Jan 4;1(1):CD004561. doi: 10.1002/14651858.CD004561.pub3. Cochrane Database Syst Rev. 2017. PMID: 28052186 Free PMC article.
-
Axillary reverse mapping in N0 patients requiring sentinel lymph node biopsy - A systematic review of the literature and necessity of a randomised study.Breast. 2017 Jun;33:57-70. doi: 10.1016/j.breast.2017.02.019. Epub 2017 Mar 8. Breast. 2017. PMID: 28282588
-
Axillary recurrence after a negative sentinel node biopsy for breast cancer: incidence and clinical significance.Ann Surg Oncol. 2005 Jan;12(1):29-33. doi: 10.1007/s10434-004-1166-0. Ann Surg Oncol. 2005. PMID: 15827775
-
Different strategies in de-escalation of axillary surgery in node-positive breast cancer following neoadjuvant treatment: a systematic review and meta-analysis of long-term outcomes.Breast Cancer. 2025 Jul;32(4):638-653. doi: 10.1007/s12282-025-01692-9. Epub 2025 Apr 5. Breast Cancer. 2025. PMID: 40186790 Free PMC article.
-
Recommendation for axillary lymph node dissection in women with early breast cancer and sentinel node metastasis: A systematic review and meta-analysis of randomized controlled trials using the GRADE system.Int J Surg. 2016 Oct;34:73-80. doi: 10.1016/j.ijsu.2016.08.022. Epub 2016 Aug 22. Int J Surg. 2016. PMID: 27562691
Cited by
-
Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial.Ann Surg Oncol. 2010 Jul;17(7):1854-61. doi: 10.1245/s10434-010-0945-z. Epub 2010 Mar 19. Ann Surg Oncol. 2010. PMID: 20300966 Free PMC article. Clinical Trial.
-
Detection capability of the Medical Imaging Projection System for sentinel lymph node biopsy in patients with breast cancer with and without neoadjuvant chemotherapy: a retrospective study.Breast Cancer. 2025 Jul;32(4):834-840. doi: 10.1007/s12282-025-01712-8. Epub 2025 May 10. Breast Cancer. 2025. PMID: 40347431 Free PMC article.
-
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.Lancet Oncol. 2014 Nov;15(12):1303-10. doi: 10.1016/S1470-2045(14)70460-7. Epub 2014 Oct 15. Lancet Oncol. 2014. PMID: 25439688 Free PMC article. Clinical Trial.
-
Survival and Prognostic Factors for Breast Cancer Patients with Regional Oligo-Recurrence.J Breast Cancer. 2020 Dec;23(6):622-634. doi: 10.4048/jbc.2020.23.e66. J Breast Cancer. 2020. PMID: 33408888 Free PMC article.
-
Sentinel node biopsy for breast cancer patients: issues for discussion and our practice.Patholog Res Int. 2010 Dec 28;2011:109712. doi: 10.4061/2011/109712. Patholog Res Int. 2010. PMID: 21234361 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical